PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026 Well-positioned to deliver on key milestones with approximately $903.0 million cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2029IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updates. “In the coming months, we look forward to sharing topline data from PIVOT-006, the first randomized registrational trial to evaluate an investigational therapy in intermediate-risk...

Fourth Quarter Highlights:GAAP net income of $0.07 per diluted common share Distributable earnings1 of $0.19, or $0.22 per diluted common share, excluding $5.1 million of net realized losses from the resolution of certain legacy assets previously reserved for Declares cash dividend on common stock of $0.30 per share Agency loan originations of $1.63 billion Structured loan originations of $1.10 billion, our strongest quarter in over three years Issued $400.0 million of 8.50% senior unsecured notes due 2028 Unwound CLO 16 with $482.1 million of outstanding notes generating ~$90 million of liquidity Foreclosed on six loans totaling $139.0 million and sold three real estate owned properties totaling $77.6 million Repurchased $20.0 million of stock at an average price of $7.40 per share, or 64% of book value, between December 2025 and February...

– Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months – – Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers – – Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Cancer 2026 Annual Congress – – Phase 2 ASPEN-09 breast cancer trial is currently enrolling patients and will evaluate...

BALLERUP, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company that manufactures and markets highly specialized filtration technologies, today announces its financial results for the fourth quarter and fiscal year 2025 for the period ended December 31, 2025. Recent Financial HighlightsFY 2025 revenue of $16.5 million, a 13% increase from $14.6 million in FY 2024. Q4 2025 revenue of $3.1 million, compared to $3.4 million in Q4 2024, an 8% decrease. FY 2025 net loss of $(8.6) million compared to $(10.3) million in FY 2024. Q4 2025 net loss of $(2.6) million compared to $(3.0) million in Q4 2024. FY 2025 Adjusted EBITDA of $(5.0) million compared to $(6.1) million in FY 2024. Ending cash balance of $5.1 million on December 31, 2025.OutlookThe...

MONTREAL, Feb. 27, 2026 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the fourth quarter and fiscal 2025. Highlights Financial resultsProduction and net earnings higher in Q4-2025Quarterly production up 18% (17% on a Combined1 basis)2 from Q4-2024, owing mainly to favourable wind conditions and the impact of newly commissioned sites, and 5% (7%) below anticipated production1. Production for fiscal 2025 is up 8% (8%) from 2024 and 8% (10%) below anticipated production; Operating income of $68 million ($85 million) in Q4-2025, down $10 million (up $32 million)3 from Q4-2024; operating income of $166 million ($248 million) for fiscal 2025, down $60 million ($19 million) from 2024; EBITDA(A)1 of $178 million ($203 million) in Q4-2025, up $9 million ($12 million)...

HOUSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) — Natural Resource Partners L.P. (NYSE:NRP) today reported fourth quarter and full year 2025 results as follows:    For the Three Months Ended     For the Year Ended  (In thousands) (Unaudited)   December 31, 2025  Net income   $ 30,998     $ 136,367  Operating cash flow   $ 44,765     $ 165,863  Free cash flow(1)   $ 45,508     $ 168,748  ____________________  (1 ) See “Non-GAAP Financial Measures” and reconciliation tables at the end of this release.2025 Highlights:Generated $169 million of free cash flow Retired $109 million of debt: $33 million of debt remaining Paid total distributions of $4.21 per common unit in 2025, consisting of $3.00 of regular distributions and a special cash distribution of $1.21 to help cover unitholder tax liabilities associated...

VANCOUVER, British Columbia, Feb. 27, 2026 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three months and year ended December 31, 2025. All dollar amounts are in US dollars ($). “2025 was a transformative year for Endeavour, marked by robust production growth, record revenues and key strategic milestones that have propelled the Company forward,” said Dan Dickson, Chief Executive Officer. “The successful commissioning of Terronera, the acquisition of Kolpa and the sale of Bolañitos Mine have not only enhanced the Company’s asset portfolio but also positioned it for sustained growth and long-term success.” “With a strong balance sheet, Endeavour has the financial flexibility to advance its strategic objectives and continue prioritizing...

Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectively Total Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectivelyQuarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectively Quarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1)Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectively Record quarterly and full year adjusted non-GAAP EBITDA of $65.4 million and $229.8 million, up 30.6% and 47.3% year-over-year, respectively Quarterly diluted GAAP income per share of $1.18 and...

LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the fourth quarter and full year ended December 31, 2025 and initiated full year 2026 Revenue and Adjusted EBITDA1 guidance. Fourth Quarter 2025 Financial Highlights(note: all figures represent continuing operations and exclude the Community Living business)Net revenue of $3,551 million, up 29.3% compared to $2,747 million in the fourth quarter of 2024 Gross profit of $413 million, up 21.8% compared to $339 million in the fourth quarter of 2024 Net income of $49.6 million compared to net income of $4.3 million in the fourth quarter of 2024 Adjusted EBITDA1 of $184 million,...

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS – BRIDGEWATER, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”)...